tbuckley/cabot-search huggingface dataset:
THU0298 Disease self-management in adolescents with chronic musculoskeletal and rheumatic diseases
Authors: A. Abou-Raya, S. Abou-Raya
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> In adolescents diagnosed with chronic rheumatologic conditions, self-management skills are an essential component of their transition to adult independent health care. <h3>Objectives</h3> The aim of this cross-sectional survey was to assess medication and exercise adherence, medical regimen knowledge and health care tasks in adolescents diagnosed with chronic rheumatic disease. <h3>Methods</h3> The study was conducted on 75 adolescents aged 13-20 years with a confirmed diagnosis of chronic rheumatic disease attending the rheumatology clinic of our institution. Exclusion criteria included cognitive impairment. Disease self-management assessment included assessing degree of medication and exercise adherence and completing health care tasks. Medication adherence wasassessed by asking participants if they missed doses of medication, frequency of doses missed per week and the reason for missing the doses. Participants were said to be adherent if they took all doses of their medication and performed the prescribed exercise programme. Medication regimen knowledge was assessed by asking patients the name, dosage and purpose of each medication. Independence in self-management tasks was assessed using a detailed 15-question survey. The participants were asked to report whether a given health care task such as refilling prescriptions and keeping a calendar of appointments was completed independently, completed with some assistance or completed by some other person. <h3>Results</h3> The mean age of the patients was 15.5 years, 77% were female, mean disease duration was 5.8 years, and mean medication usage was 3.2 (2.3). Fifty-one percent had juvenile idiopathic arthritis, 28 (37%) had systemic lupus erythematosus, 3% had dermatomyositis, 4% had systemic sclerosis, 3% had ankylosing spondylitis, 1% had Behcet's Disease and 1% had Familial Meditteranean disease. Fifty-six per cent and 37% reported complete adherence to medications and exercise prescription respectively. Forty-five per cent reported missing 1-2 medication doses per week, 51% knew medication names, 72% knew correct dosage regimens and 52% knew the purpose of their medication. The most common cause for missing medication was forgetfulness. For health care tasks, 69% knew symptoms of their disease, 64% asked their doctors questions, 19% scheduled their own medical and/or laboratory appointments, 20% got their prescriptions refilled and 17% had their own medical file. Health care self-tasks failed to improve with increasing age. <h3>Conclusions</h3> The findings of the present study indicate that adolescents with chronic musculoskeletal and rheumatic diseases have inadequate self-management skills. Additional patient education interventions and support is required to enable them to take better control of their illness and thereby improve health outcomes and quality of lifeas these adolescents enter into adult life. <h3>Disclosure of Interest</h3> None Declared
Multidrug Resistance in<i>Yersinia pestis</i>Mediated by a Transferable Plasmid
Authors: Marc Galimand, Annie Guiyoule, Guy Gerbaud, Bruno Rasoamanana, Suzanne Chanteau, Elisabeth Carniel, Patrice Courvalin
Journal: New England Journal of Medicine (1997)

Yersinia pestis is the causative agent of plague, a zoonotic disease transmitted to humans through flea bites and typically characterized by the appearance of a tender and swollen lymph node, the bubo. Human-to-human transmission can occur, through either the bite of fleas (bubonic plague) or respiratory droplets, causing an overwhelming infection called pneumonic plague. The last plague pandemic began in Hong Kong in 1894 and spread throughout the world, establishing many endemic foci. Antibiotics and enforcement of public health measures significantly decreased the morbidity and mortality associated with the disease but did not allow its eradication. In fact, plague . . .
Abstract 2840: Development of a bioluminescent cell-based bioassay to measure Fc receptor functionality in antibody-dependent cellular cytotoxicity
Authors: Zhi-jie J. Cheng, Shan Chung, Denise Garvin, Rich Moravec, Aileen Paguio, Valerie Quarmby, Frank Fan, Teresa K. Surowy
Journal: Cancer Research (2012)

Abstract Primary peripheral blood mononuclear cells (PBMCs) are routinely used in traditional bioassays to quantify antibody drug potency in antibody-dependent cellular cytotoxicity (ADCC). These bioassays are labor intensive and have high inherent assay variability. Here, we report the development of a bioluminescent cell-based bioassay which measures activation of effector cells via cross-linking of FcαRIIIA with target cell-bound antibodies. For this, Jurkat T-cell stable cell lines that stably express NFAT-luciferase reporter and human FcαRIIIA were generated to replace primary PBMCs as effector cells in ADCC bioassay. Effector cells were also developed in a frozen, thaw-and-use format, to minimize assay variability due to cell culture and handling. The resultant bioassay using this format demonstrated good assay precision and accuracy in bioassay qualification. Bioassay using the engineered effector cells is robust, specific and is able to quantify the potencies of rituximab and trastuzumab, two monoclonal antibody drugs for cancer. When used to measure effects of Fc glycosylation on effector functions of therapeutic antibodies, a linear correlation was observed between relative antibody activity and the extent of Fc glycosylation. Thus, the bioluminescent cell-based reporter bioassay provides a simple and robust approach to measure potency of therapeutic antibodies in ADCC with high precision. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2840. doi:1538-7445.AM2012-2840
Endoscopic treatment of a cystic duct stump leak complicated by aberrant bile duct communication
Authors: Bulent Odemis, Erkin Oztas, Serkan Torun, Nuretdin Suna
Journal: Endoscopy (2015)

A 53-year-old man was referred to our clinic with the problem of continuous bile drainage (approximately 200 mL bile per day) that was still occurring 10 days after an intra-abdominal drain had been placed into the operation area following a laparoscopic cholecystectomy. At endoscopic retrograde cholangiography (ERC), a stone was detected at the distal site of the common bile duct (CBD), sphincterotomy was performed, and the stone was extracted via balloon. During ERC, injection of contrast medium together with balloon occlusion revealed the presence of a leak from the cystic stump at the level of the percutaneous drain ([Fig. 1 a]). Surprisingly, the endoscopist also noticed that intrahepatic ducts in a segment of the right posterior hepatic lobe were not filled during balloon occlusion cholangiogram ([Fig. 1 a]).
Canadian doctors try to garner public support to fight pay freeze
Authors: B. Kermode-Scott
Journal: BMJ (2012)

A dispute between the government of Ontario and the province’s medical profession over the remuneration of doctors that exploded in early May has spread to the rest of Canada. The Ontario government and Ontario Medical Association have sought and gained allies from across Canada as they engage in a battle to win public opinion.

Ontario’s provincial government took the first shot in the current war of words on 7 May 2012 when Premier Dalton McGuinty’s government withdrew from negotiations with the medical profession and announced that Ontario was imposing “a real wage freeze” for doctors to invest “more …
Abstract 424: Interference with alphaVbeta3 integrins via cyclic RGD peptides affects breast cancer cell behavior
Authors: Alexandra Martel, Marina Poettler, Waclawa Kalinowska, Peter Valent, Christoph Zielinski, Gerald W. Prager
Journal: Cancer Research (2011)

Abstract Integrin alphavbeta3 is mainly expressed in stimulated endothelial cells, thus it has recently become the focus of intense research mainly to interfere with tumorangiogenesis. However, alphavbeta3 integrins are also expressed in a variety of tumor cells, such as melanoma, prostate cancer, breast cancer, cervix carcinoma or pancreatic cancer. While inhibition of integrin alphavbeta3 activity in endothelial cells has been studied extensively, any direct effects on integrin alphavbeta3 expressing tumor cells is hitherto unknown. In this study we examined alphavbeta3 integrin expression in breast cancer cell lines, where by MDA MB 231 revealed high integrin alphavbeta3 as well as VEGFR-2 and VEGF expression. While adhesion of MDA MB231 cells to an alphavbeta3 specific matrix such as fibrinogen was blocked by the addition of cyclic RGD peptides, sequentially addition of cyclic RGD peptides to already adherent MDA MB231 cells led to a diminished spreading in a time and dose dependent manner, starting at 20nM. Furthermore, tumor cell migration as well as transmigration through an EC monolayer upon VEGF stimulation was blocked whenever alphavbeta3 integrins were targeted by RGD mimetic peptide. Our data give first functional insights into the previously described effects of alphavbeta3 targeting small molecules, which led to a reduced breast cancer metastasis in vivo. Thus interfering with alphavbeta3 integrins on tumor cells might represent a promising therapeutic lead in certain malignancies. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 424. doi:10.1158/1538-7445.AM2011-424
AB0311 The 158vv fcgamma receptor iiia genotype predicts a positive response to rituximab in rheumatoid arthritis: Analysis in a large cohort of italian patients
Authors: M. Fabris, L. Quartuccio, E. Pontarini, A. Zabotti, M. Benucci, M. Manfredi, D. Biasi, V. Ravagnani, F. Atzeni, P. Morassi, F. Fischetti, L. Bazzicchi, M. Saracco, R. Pellerito, M. Cimmino, V. Carraro, A. Semeraro, R. Caporali, L. Cavagna, R. Bortolotti, M. Govoni, S. Bombardieri, S. De Vita
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Receptors for IgG play an important part in immune complex clearance. Several studies have investigated the polymorphism 158V/F of Fc fragment of IgG (FcgR) type IIIa as genetic factor influencing disease course after rituximab (RTX) therapy in several rheumatologic and haematological diseases, with contrasting, unreplicated results. <h3>Objectives</h3> To investigate the FcgRIIIa 158V/F polymorphism in a large Italian retrospective cohort of patients with rheumatoid arthritis treated with RTX. <h3>Methods</h3> The study was conducted in 222 unselected RA patients referred to 13 rheumatologic centres in Italy. All patients were treated with RTX (alone or in combination with DMARDs) at standard doses. Response to therapy (DAS28; EULAR criteria) was evaluated at months +4 (data available in 213 cases) and +6 (data available in all cases) after the first RTX infusion. The FcgRIIIa polymorphism was analysed by PCR followed by Sanger’s sequencing. <h3>Results</h3> Patients with the VV genotype showed the highest rate of response to RTX both at month +4 (good/moderate in 32/37, 86.5% of the VV patients) and at month +6 (good/moderate response in 34/38, 89.5% of the VV patients) while VF and FF patients showed the same response rate either at month +4 (good/moderate in 70/103, 68% VF and in 53/73, 72.6% FF patients; VV versus VF/FF: OR 2.76, 95%CI 1.02-7.47, *p=0.043) and at month +6 (good/moderate in 69/105, 65.7% VF and in 49/75, 65.3% FF patients; VV versus VF/FF: OR 4.47, 95%CI 1.52-13.16, **p=0.0032). <h3>Conclusions</h3> The VV genotype of the 158V/F FcgRIIIa polymorphism identifies RA patients who demonstrate the highest rate of positive response to RTX. By contrast, no difference was noticed between VF and FF patients. <h3>Disclosure of Interest</h3> None Declared
423 THE COMBINATION OF HBsAg AND HBV CORE-RELATED ANTIGEN (HBcrAg) MEASUREMENT IS USEFUL FOR DISCRIMINATING HBeAg NEGATIVE INACTIVE CARRIER AND EVALUATING THE RISK OF HCC
Authors: T. Nakata, M. Kurosaki, S. Matsuda, Y. Muraoka, Y. Suzuki, N. Tamaki, S. Suzuki, Y. Yasui, T. Hosokawa, T. Nishimura, K. Ueda, H. Nakanishi, K. Tsuchiya, J. Itakura, N. Izumi
Journal: Journal of Hepatology (2013)
Usefullness of EUS and EUS-FNAB for the metastatic pancreas cancers
Authors: Haba Shin
Journal: Endoscopy (2011)

Background & Aim: Though the metastatic lesions of the pancreas are rare, they represent a subtle cause of focal pancreatic lesions with difficulties in diagnosis by imaging alone. Also, reports described its EUS & EUS-FNAB findings were scarce. Hereby, we studied the effectiveness of EUS and EUS-FNAB utility for metastatic pancreatic lesions.
Generation of T Cells from Human Embryonic Stem Cells.
Authors: Frank Timmermans, Imke Velghe, Lieve Van Walleghem, Magda De Smedt, Stefanie Van Coppernolle, Georges Leclercq, Tom Taghon, Harry Moore, Anton W Langerak, Tessa C. C. Kerre, Jean Plum, Bart Vandekerckhove
Journal: Blood (2008)
Reply to Sarkis et al.
Authors: A. Repici, C. Hassan, A. Zullo
Journal: Endoscopy (2012)

We are grateful to Sarkis et al. for reporting their series of over 7000 cold biopsies during colonoscopy that showed a very low rate of delayed bleeding (i. e., 0.07 %) without the need for transfusion in any of the five cases [1]. The authors also successfully documented the presence of potential patient-related or lesion-related factors that could have caused a delayed bleeding, such as the use of antiplatelet or other drugs. The authors conclude that patient-related and lesion-related risk factors should be cautiously evaluated, before performance of cold biopsy or cold polypectomy.
Abstract P5-11-07: ER Positive Screen Detected Breast Cancers (SDBC) Do Not Require Chemotherapy
Authors: NJ Bundred, J Morris, S Cheung, WF Knox, G. Lawrence
Journal: Cancer Research (2010)

Abstract Background: Meta-analysis of symptomatic breast cancer trials advises chemotherapy to women less than 70 years of age at high risk of death (i.e benefit of &amp;gt;1% survival benefit from treatment) but UK screen detected breast cancers (SDBC) in women aged 50 to 65 years have a 97.2% relative survival compared to 77.6% for symptomatic cancers in the ABS at BASO audit. Methods: To determine which women benefit from chemotherapy, we have analysed 1,607 symptomatic and SDBC in one unit. Results: SDBC had a significantly lower risk of relapse with the five year breast cancer mortality for ER positive breast cancers being low in the Excellent, Good and Moderate Prognostic Group 1 but being significantly higher in the Good Prognostic Group and Moderate Prognostic Group 1 diagnosed symptomatically. Symptomatic cancers in the Good Prognostic Group (GPG) and Moderate Prognostic Group 1 (MPG1) had a hazard ratio of 5.34 (1.61-17.75) and 14.46 (10.4-106.0) respectively for cancer death compared to SDBC. NPI Index Score and Mortality in SDBC and Symptomatic Cancers treated in Manchester 1990-98 - ER ER positive cancers detected by screening (but not ER negative) had a 0.6% mortality annually whereas the symptomatic cancers had a 10% annual mortality in the first five years. The UK National ABS/BASO Audit was used to confirm the findings (Table 2). Data over the last ten years of follow-up from the ABS at BASO audit indicates significant survival improvements in the Moderate Prognostic Group 2 (MPG2) and the Poor Prognostic Group (PPG) for SDBC. NHSBSP and ABS at BASO Breast Screening National Audit Data for Invasive SDBCs diagnosed between 1990 and 2002 Discussion: Thus, ER positive SDBCs represent a group which have a low risk of relapse and do not require chemotherapy. The improvements in survival of SDBC relate to better treatment of ER negative and HER2 positive breast cancers and have occurred predominantly in the MPG2 and PPG. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P5-11-07.
397 OXIDATIVE STRESS, SP1, AND SP3 TRANSCRIPTION FACTORS ARE INVOLVED IN THE INCREASED COLLAGEN GENE EXPRESSION INDUCED BY LEPTIN
Authors: É. Gómez-Izquierdo, I. García-Ruiz, T. Díaz-Sanjuán, P. Solís-Muñoz, T. Muñoz-Yagüe, J.A. Solís-Herruzo
Journal: Journal of Hepatology (2012)
Abstract 4860: Exon capture analysis of G-protein coupled receptors reveals activating mutations in <i>GRM3</i> in melanoma
Authors: Todd D. Prickett, Xiaomu Wei, Isabel Cardenas-Navia, Jamie Teer, Jimmy C. Lin, Vijay Walia, Jared Gartner, Jiji Jiang, Praveen Cherukuri, Alfredo Molinolo, Michael A. Davies, Katherine Stamke-Hale, Elliott H. Margulies, Steven A. Rosenberg, Yardena Samuels
Journal: Cancer Research (2012)

Abstract An important feature of cellular signaling involves the activation of plasma membrane-bound receptor complexes via endogenous ligands. G protein-coupled receptors (GPCRs), the largest human gene family, are known to be activated by ligands such as, thrombin, chemokines or glutamate, and have been shown to be important regulators of signaling pathways. Dysregulation via overexpression of diverse GPCRs has been well documented in primary and metastatic tumors cells such as breast, lung, prostate and gastric tumors, head and neck squamous cell carcinoma, and melanoma (1), however, knowledge of their genetic alterations is limited especially in malignant melanoma. Thus, further analysis of this gene family is warranted to determine if GPCR proteins play a role in melanomagenesis. In our current study, we used exon capture and illumina sequencing methods to analyze the mutational status of all the GPCRs in melanoma. This investigation revealed that one family member, GRM3 was frequently mutated in melanoma and that one of its mutations clustered within one position (Glu870Lys). Biochemical analysis of GRM3 alterations revealed that mutant GRM3 selectively regulated the phosphorylation of MEK leading to increased anchorage-independent growth and migration. In vivo studies revealed that overexpression of mutant forms of GRM3 result in increased lung macrometastases; whereas depletion of GRM3 in cells expressing mutant forms of GRM3 resulted in reduced xenograft tumor formation compared to equivalently treated wild type GRM3 cells. Furthermore, melanoma cells expressing mutant forms of GRM3 had reduced cell growth and reduced cellular migration after shRNA-mediated knockdown of GRM3 or treatment with a selective MEK inhibitor, AZD-6244, which is currently being used in phase II clinical trials. Our study yields a comprehensive map of genetic alterations in the GPCR gene family and suggests a potential novel therapeutic target for melanoma patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4860. doi:1538-7445.AM2012-4860
Abstract 5044: Radiation modulates expression of microRNAs in breast cancer cell lines grown under adherent and stem cell promoting culture conditions
Authors: Bisrat G. Debeb, Wei Xu, Lara Lacerda, Li Li, Wei Caimiao, James M. Reuben, Naoto T. Ueno, Thomas A. Buchholz, Wendy A. Woodward
Journal: Cancer Research (2012)

Abstract Although mounting evidence demonstrates that cancer stem/progenitor cells are radioresistant, explicit mechanisms of resistance have not been fully explored. MicroRNAs (miRNAs) are small noncoding RNAs that are involved in regulating cancer stem cell self-renewal and play an important role in response to cellular stress. Few studies have been conducted to investigate the role of specific miRNAs in cellular radiation response. Knowledge of how radiation therapy modulates miRNA expression in cancer stem cells vs. non-stem cells is critical to developing cancer stem cell sensitizers. We isolated total RNA from adherent (2D) and non-adherent mammosphere (3D) cultures of six breast cancer cell lines (MCF12F, MCF7, SUM190, SUM149, MDA-IBC-3, and SUM159) subjected to 0Gy or 4Gy radiation and examined differentially expressed miRNAs using Exiqon's miRCURY microarray. Analysis of the data showed 62 differentially expressed miRNAs between 2D and 3D independent of radiation treatment (fold change of at least 1.5, FDR &amp;lt;0.1; P&amp;lt;0.05). While no radiation based signature was observed when comparing all irradiated samples to unirradiated samples, assessment of each cell line indicated that the levels of specific microRNAs were altered in response to radiation treatment in 2D and 3D cells. Further studies to validate the functions of top candidate miRNAs using inhibitors or mimics to alter the self renewal and radiosensitivity of cancer stem cells are underway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5044. doi:1538-7445.AM2012-5044
Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial
Authors: Gérald Simonneau, Andrea M D'Armini, Hossein-Ardeschir Ghofrani, Friedrich Grimminger, Pavel Jansa, Nick H Kim, Eckhard Mayer, Tomas Pulido, Chen Wang, Pablo Colorado, Arno Fritsch, Christian Meier, Sylvia Nikkho, Marius M Hoeper
Journal: The Lancet Respiratory Medicine (2016)
566 PROTON NMR SERUM METABOLOMIC FINGERPRINT OF ACUTE ON CHRONIC LIVER FAILURE (AOCLF) IN ICU CIRRHOTIC PATIENTS
Authors: R. Amathieu, M.N. Triba, P. Nahon, N. Bouchemal, W. Kamoun, H. Haouache, J.-C. Trinchet, G. Dhonneur, L. Le Moyec
Journal: Journal of Hepatology (2012)
Opsonophagocytic Killing Antibody to<i>Pseudomonas aeruginosa</i>Mucoid Exopolysaccharide in Older Noncolonized Patients with Cystic Fibrosis
Authors: Gerald B. Pier, James M. Saunders, Peter Ames, Morven S. Edwards, Harvey Auerbach, Johanna Goldfarb, David P. Speert, Sandra Hurwitch
Journal: New England Journal of Medicine (1987)

The principal cause of morbidity and mortality in cystic fibrosis is persistent respiratory colonization with mucoid strains of Pseudomonas aeruginosa. To investigate possible mechanisms of resistance to this organism, we studied serum from 16 older (greater than or equal to 12 years) patients not colonized with mucoid P. aeruginosa, 11 older (greater than or equal to 14 years) colonized patients, 10 younger (less than or equal to 11 years) noncolonized patients, and 20 healthy adults. The samples from the older patients not colonized with mucoid P. aeruginosa contained antibody specific to the mucoid-exopolysaccharide antigen, which could mediate bacterial killing in conjunction with complement and white cells (titers of 4 to 80). These opsonophagocytic killing antibodies were not detected in samples from the 20 normal controls (P less than 0.0001 vs. noncolonized older patients) or 9 of 10 younger (less than or equal to 11 years) noncolonized patients (P = 0.0072 vs. noncolonized older patients). Although the patients with chronic colonization had higher titers of serum opsonophagocytic killing antibody than did the older noncolonized patients (P = 0.0005), these antibodies were not specific to the mucoid-exopolysaccharide antigen. We conclude that there is an association between mucoid-exopolysaccharide-specific opsonophagocytic killing antibody and a lack of detectable P. aeruginosa colonization in a subset of older, relatively healthy patients with cystic fibrosis.